J&J’s Ortho Clinical Diagnostics Business Snapped up by Carlyle Group for $4.15 Billion in a Sale that Will Impact OCD’s Clinical Laboratory Customers

Jan 20, 2014 | Laboratory News

It’s finally official! Ortho Clinical Diagnostics  (OCD) will be sold to The Carlyle Group (CG: NASDAQ), an asset management firm and equity investor. The sales agreement was announced on Thursday. Carlyle will pay $4.15 billion, and the transaction is expected to close mid-year, pending regulatory approvals. OCD’s change of ownership will be closely watched by the thousands of medical laboratories in the United States and abroad that are customers of OCD. Typically, pathologists and clinical...

Johnson & Johnson Says It Is ‘Exploring All Options’ for Selling, or Spinning Off, Its Ortho Clinical Diagnostics Unit That Sells Clinical Laboratory Products

Jan 28, 2013 | Laboratory News, Laboratory Pathology, Laboratory Sales and Marketing, Management & Operations

Any change of ownership in the fifth largest in vitro diagnostics company would represent a major development in the medical laboratory testing marketplace Medical laboratory managers may see more consolidation in the in vitro diagnostics market if executives at Johnson & Johnson (NYSE: JNJ) decide to sell its Ortho Clinical Diagnostics (OCD) unit. This decision was announced earlier this week during J&J’s conference call to discuss its fourth quarter 2012 financial report. Ortho...
;